Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin continuation for HER2-overexpressing tumors
NCT02721641Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 1999
- Primary completion
- Feb 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of trastuzumab in Human epidermal growth factor receptor 2 positive cancer, sponsored by Roche. Started Jun 1999; status: completed.
02
Drugs
03
Conditions
Human epidermal growth factor receptor 2 positive cancer
Beyond the preview
Go deeper on NCT02721641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721641.